Aytu BioPharma (AYTU) Stock Forecast, Price Target & Predictions
AYTU Stock Forecast
Aytu BioPharma stock forecast is as follows:
Aytu BioPharma Financial Forecast
Aytu BioPharma Revenue Forecast
| Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $22.93M | - | - | $22.73M | $26.28M | - | - | $24.20M | $23.13M | $21.90M | $23.48M | $13.48M | $15.15M | $13.52M | $14.86M | $8.16M | $3.18M | $1.44M | $1.72M | $2.38M | $1.79M | $1.43M | $607.00K | $1.05M | $1.08M | $836.00K | $894.00K |
| Avg Forecast | $23.08M | $18.30M | $17.35M | $21.75M | $27.73M | $27.69M | $28.00M | $29.50M | $24.30M | $25.70M | $24.20M | $23.10M | $22.10M | $24.70M | $14.03M | $12.25M | $13.33M | $11.24M | $5.81M | $2.74M | $2.02M | $1.77M | $2.04M | $1.54M | $1.06M | $7.53M | $2.10M | $4.66M | $1.74M | $679.88K |
| High Forecast | $23.08M | $18.30M | $17.35M | $21.75M | $27.73M | $27.69M | $28.00M | $29.50M | $24.30M | $25.70M | $24.20M | $23.10M | $22.10M | $24.70M | $14.03M | $12.25M | $13.33M | $11.24M | $5.81M | $2.74M | $2.02M | $1.77M | $2.04M | $1.85M | $1.27M | $9.04M | $2.52M | $5.60M | $2.08M | $815.85K |
| Low Forecast | $23.08M | $18.30M | $17.35M | $21.75M | $27.73M | $27.69M | $28.00M | $29.50M | $24.30M | $25.70M | $24.20M | $23.10M | $22.10M | $24.70M | $14.03M | $12.25M | $13.33M | $11.24M | $5.81M | $2.74M | $2.02M | $1.77M | $2.04M | $1.23M | $847.40K | $6.02M | $1.68M | $3.73M | $1.39M | $543.90K |
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 16 | 15 | 18 | 8 | 13 | 7 |
| Surprise % | - | - | - | 1.05% | - | - | 0.81% | 0.89% | - | - | 1.00% | 1.00% | 0.99% | 0.95% | 0.96% | 1.24% | 1.01% | 1.32% | 1.40% | 1.16% | 0.71% | 0.97% | 1.17% | 1.17% | 1.35% | 0.08% | 0.50% | 0.23% | 0.48% | 1.31% |
Aytu BioPharma's average Quarter revenue forecast for Mar 24 based on 0 analysts is $17.35M, with a low forecast of $17.35M, and a high forecast of $17.35M. AYTU's average Quarter revenue forecast represents a -24.37% decrease compared to the company's last Quarter revenue of $22.93M (Dec 23).
Aytu BioPharma EBITDA Forecast
| Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 16 | 15 | 18 | 8 | 13 | 7 |
| EBITDA | - | - | - | $2.36M | - | - | $-9.19M | $-819.00K | - | - | $36.76M | $-8.34M | $14.10M | $-5.19M | $-7.30M | $-83.61K | $-1.47M | $-8.69M | $-3.17M | $-8.88M | $-3.87M | $5.99M | $-3.55M | $-3.90M | $-2.86M | $-3.25M | $-3.33M | $-3.70M | $-1.73M | $-4.32M |
| Avg Forecast | $-6.24M | $-4.95M | $-93.85M | $-5.88M | $-7.50M | $-7.49M | $-100.38M | $-7.98M | $-18.91M | $-6.95M | $-107.36M | $-11.02M | $-20.23M | $-6.68M | $-43.97M | $-3.42M | $-2.66M | $-3.04M | $-4.89M | $1.89M | $-3.48M | $-479.99K | $-4.27M | $-3.32M | $-1.82M | $-3.40M | $-3.80M | $-5.42M | $-4.09M | $-3.17M |
| High Forecast | $-6.24M | $-4.95M | $-75.08M | $-5.88M | $-7.50M | $-7.49M | $-80.30M | $-7.98M | $-15.13M | $-6.95M | $-85.89M | $-8.81M | $-16.18M | $-6.68M | $-35.18M | $-2.74M | $-2.12M | $-3.04M | $-3.91M | $2.27M | $-2.78M | $-479.99K | $-3.42M | $-2.65M | $-1.46M | $-2.72M | $-3.04M | $-4.33M | $-3.27M | $-2.54M |
| Low Forecast | $-6.24M | $-4.95M | $-112.63M | $-5.88M | $-7.50M | $-7.49M | $-120.46M | $-7.98M | $-22.70M | $-6.95M | $-128.83M | $-13.22M | $-24.27M | $-6.68M | $-52.77M | $-4.11M | $-3.19M | $-3.04M | $-5.87M | $1.51M | $-4.18M | $-479.99K | $-5.12M | $-3.98M | $-2.19M | $-4.08M | $-4.56M | $-6.50M | $-4.91M | $-3.81M |
| Surprise % | - | - | - | -0.40% | - | - | 0.09% | 0.10% | - | - | -0.34% | 0.76% | -0.70% | 0.78% | 0.17% | 0.02% | 0.55% | 2.86% | 0.65% | -4.69% | 1.11% | -12.47% | 0.83% | 1.17% | 1.57% | 0.96% | 0.88% | 0.68% | 0.42% | 1.36% |
0 analysts predict AYTU's average Quarter EBITDA for Mar 24 to be $-93.85M, with a high of $-75.08M and a low of $-112.63M. This is -4070.17% lower than Aytu BioPharma's previous annual EBITDA (Dec 23) of $2.36M.
Aytu BioPharma Net Income Forecast
| Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 16 | 15 | 18 | 8 | 13 | 7 |
| Net Income | - | - | - | $-220.00K | - | - | $-5.84M | $-10.39M | - | - | $-140.25M | $-11.55M | $-27.85M | $-19.00M | $-37.33M | $-9.53M | $-5.05M | $4.87M | $-5.33M | $-214.25K | $-5.12M | $-34.30M | $-4.70M | $-4.74M | $-3.40M | $-2.82M | $-3.67M | $-3.95M | $-8.02M | $-5.22M |
| Avg Forecast | $8.53M | $-2.49M | $-98.79M | $-1.38M | $-221.34K | $-5.26M | $-105.66M | $-3.87M | $-20.84M | $-26.56M | $-113.01M | $-14.34M | $-22.28M | $-45.24M | $-58.39M | $-4.29M | $-5.17M | $-38.62M | $-7.03M | $-377.61K | $-4.22M | $-364.17M | $-5.12M | $-3.88M | $-2.23M | $-4.87M | $-4.96M | $-6.76M | $-9.21M | $-3.60M |
| High Forecast | $8.53M | $-2.49M | $-79.03M | $-1.38M | $-221.34K | $-5.26M | $-84.53M | $-3.87M | $-16.67M | $-26.56M | $-90.41M | $-11.47M | $-17.83M | $-45.24M | $-46.71M | $-3.43M | $-4.13M | $-38.62M | $-5.62M | $-302.09K | $-3.38M | $-364.17M | $-4.09M | $-3.10M | $-1.79M | $-3.89M | $-3.97M | $-5.41M | $-7.37M | $-2.88M |
| Low Forecast | $8.53M | $-2.49M | $-118.55M | $-1.38M | $-221.34K | $-5.26M | $-126.79M | $-3.87M | $-25.00M | $-26.56M | $-135.61M | $-17.20M | $-26.74M | $-45.24M | $-70.07M | $-5.14M | $-6.20M | $-38.62M | $-8.43M | $-453.13K | $-5.07M | $-364.17M | $-6.14M | $-4.65M | $-2.68M | $-5.84M | $-5.95M | $-8.11M | $-11.05M | $-4.33M |
| Surprise % | - | - | - | 0.16% | - | - | 0.06% | 2.68% | - | - | 1.24% | 0.81% | 1.25% | 0.42% | 0.64% | 2.22% | 0.98% | -0.13% | 0.76% | 0.57% | 1.21% | 0.09% | 0.92% | 1.22% | 1.52% | 0.58% | 0.74% | 0.58% | 0.87% | 1.45% |
Aytu BioPharma's average Quarter net income forecast for Sep 20 is $-5.17M, with a range of $-6.20M to $-4.13M. AYTU's average Quarter net income forecast represents a -206.13% decrease compared to the company's last Quarter net income of $4.87M (Jun 20).
Aytu BioPharma SG&A Forecast
| Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 16 | 15 | 18 | 8 | 13 | 7 |
| SG&A | - | - | - | $12.02M | - | - | $19.98M | $18.58M | - | - | $17.36M | $17.61M | $17.51M | $19.98M | $12.85M | $12.85M | $11.49M | $13.64M | $9.50M | $6.52M | $5.15M | $4.90M | $5.38M | $5.14M | $3.83M | $4.64M | $4.55M | $4.62M | $3.74M | $4.42M |
| Avg Forecast | $28.22M | $22.38M | $21.21M | $26.59M | $33.90M | $33.86M | $34.24M | $36.07M | $13.10M | $31.42M | $29.59M | $21.86M | $14.01M | $30.20M | $17.16M | $5.78M | $16.30M | $13.74M | $7.10M | $3.35M | $2.46M | $2.17M | $2.49M | $1.88M | $1.30M | $9.21M | $2.57M | $5.70M | $2.12M | $831.27K |
| High Forecast | $28.22M | $22.38M | $21.21M | $26.59M | $33.90M | $33.86M | $34.24M | $36.07M | $15.72M | $31.42M | $29.59M | $26.24M | $16.82M | $30.20M | $17.16M | $6.94M | $16.30M | $13.74M | $7.10M | $3.35M | $2.46M | $2.17M | $2.49M | $2.26M | $1.55M | $11.05M | $3.08M | $6.84M | $2.55M | $997.53K |
| Low Forecast | $28.22M | $22.38M | $21.21M | $26.59M | $33.90M | $33.86M | $34.24M | $36.07M | $10.48M | $31.42M | $29.59M | $17.49M | $11.21M | $30.20M | $17.16M | $4.63M | $16.30M | $13.74M | $7.10M | $3.35M | $2.46M | $2.17M | $2.49M | $1.50M | $1.04M | $7.37M | $2.05M | $4.56M | $1.70M | $665.02K |
| Surprise % | - | - | - | 0.45% | - | - | 0.58% | 0.52% | - | - | 0.59% | 0.81% | 1.25% | 0.66% | 0.75% | 2.22% | 0.71% | 0.99% | 1.34% | 1.95% | 2.09% | 2.26% | 2.16% | 2.73% | 2.96% | 0.50% | 1.77% | 0.81% | 1.76% | 5.32% |
Aytu BioPharma's average Quarter SG&A projection for Mar 24 is $21.21M, based on 0 Wall Street analysts, with a range of $21.21M to $21.21M. The forecast indicates a 76.52% rise compared to AYTU last annual SG&A of $12.02M (Dec 23).
Aytu BioPharma EPS Forecast
| Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | 4 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 16 | 15 | 18 | 8 | 13 | 7 |
| EPS | - | - | - | - | - | - | $-1.57 | $-3.34 | - | - | $-94.48 | $-8.74 | $-21.76 | $-16.15 | $-41.27 | $-25.67 | $-8.31 | $8.59 | $-33.29 | $111.05 | $-66.83 | $-1.12 | $-103.64 | $-146.47 | $-386.31 | $-517.64 | $-3.07K | $-3.74K | $-38.91K | $-31.93K |
| Avg Forecast | $1.54 | $-0.45 | $-0.64 | $-0.25 | $-0.04 | $-0.95 | $-0.63 | $-0.70 | $-3.60 | $-4.80 | $-22.00 | $-8.80 | $-9.80 | $-8.20 | $-6.67 | $-8.80 | $-11.00 | $-7.00 | $-10.00 | $-51.00 | $-55.00 | $-66.00 | $-116.00 | $-0.32 | $-0.94 | $-34.54 | $-48.06 | $-241.92 | $-234.72 | $-101.34 |
| High Forecast | $1.54 | $-0.45 | $-0.64 | $-0.25 | $-0.04 | $-0.95 | $-0.63 | $-0.70 | $-3.60 | $-4.80 | $-22.00 | $-8.80 | $-9.80 | $-8.20 | $-6.67 | $-8.80 | $-11.00 | $-7.00 | $-10.00 | $-51.00 | $-55.00 | $-66.00 | $-116.00 | $-0.26 | $-0.75 | $-27.63 | $-38.45 | $-193.54 | $-187.78 | $-81.07 |
| Low Forecast | $1.54 | $-0.45 | $-0.64 | $-0.25 | $-0.04 | $-0.95 | $-0.63 | $-0.70 | $-3.60 | $-4.80 | $-22.00 | $-8.80 | $-9.80 | $-8.20 | $-6.67 | $-8.80 | $-11.00 | $-7.00 | $-10.00 | $-51.00 | $-55.00 | $-66.00 | $-116.00 | $-0.39 | $-1.13 | $-41.45 | $-57.67 | $-290.30 | $-281.66 | $-121.61 |
| Surprise % | - | - | - | - | - | - | 2.49% | 4.77% | - | - | 4.29% | 0.99% | 2.22% | 1.97% | 6.19% | 2.92% | 0.76% | -1.23% | 3.33% | -2.18% | 1.22% | 0.02% | 0.89% | 457.72% | 410.97% | 14.99% | 63.85% | 15.44% | 165.77% | 315.09% |
According to 7 Wall Street analysts, Aytu BioPharma's projected average Quarter EPS for Sep 20 is $-11.00, with a low estimate of $-11.00 and a high estimate of $-11.00. This represents a -228.06% decrease compared to AYTU previous annual EPS of $8.59 (Jun 20).
Aytu BioPharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FLGC | Flora Growth | $1.16 | $173.50 | 14856.90% | Hold |
| ESPR | Esperion Therapeutics | $1.78 | $16.00 | 798.88% | Buy |
| AYTU | Aytu BioPharma | $2.53 | $11.00 | 334.78% | - |
| IRWD | Ironwood Pharmaceuticals | $4.48 | $11.67 | 160.49% | Buy |
| AQST | Aquestive Therapeutics | $4.79 | $9.50 | 98.33% | Buy |
| LFCR | Lifecore Biomedical | $5.08 | $8.00 | 57.48% | Buy |
| AVDL | Avadel Pharmaceuticals | $13.83 | $14.75 | 6.65% | Buy |
| ALIM | Alimera Sciences | $5.54 | $5.75 | 3.79% | Hold |
| GHSI | Guardion Health Sciences | $10.19 | $0.01 | -99.90% | Buy |
AYTU Forecast FAQ
Did the AYTU's actual financial results beat the analysts' financial forecasts?
Based on Aytu BioPharma's last annual report (Jun 2021), the company's revenue was $65.63M, beating the average analysts forecast of $64.31M by 2.05%. Apple's EBITDA was $-14.491M, missing the average prediction of $-56.728M by -74.46%. The company's net income was $-58.289M, missing the average estimation of $-113M by -48.46%. Apple's SG&A was $55.81M, missing the average forecast of $69.44M by -19.63%. Lastly, the company's EPS was $-69.61, beating the average prediction of $-34.667 by 100.80%. In terms of the last quarterly report (Dec 2023), Aytu BioPharma's revenue was $22.93M, beating the average analysts' forecast of $21.74M by 5.47%. The company's EBITDA was $2.36M, missing the average prediction of $-5.88M by -140.20%. Aytu BioPharma's net income was $-220K, missing the average estimation of $-1.383M by -84.10%. The company's SG&A was $12.02M, missing the average forecast of $26.59M by -54.81%. Lastly, the company's EPS was $0, missing the average prediction of $-0.25 by -100.00%